Scholarlink

<p>Immune checkpoint inhibitors (ICIs) have transformed treatment for advanced non-small cell lung cancer (NSCLC) treatment but can trigger immune-related adverse events (irAEs). Evidence on clinically meaningful irAEs in first-line ICI settings is limited. Using the SEER-Medicare data (2010–2019), we conducted a population-based retrospective study of adults aged ≥ 66 years with advanced NSCLC initiating first-line nivolumab, pembrolizumab, or atezolizumab. Severe irAEs were defined as immune-related events requiring systemic immunosuppressants and resulting in ICI delay or discontinuation occurring after treatment initiation. Fine-Gray competing risks models were used to identify predictors of irAE, and model performance was evaluated using bootstrap and ten-fold cross-validation. Among 2,729 patients, 14.2% developed severe irAEs (median onset = 1.4 months; IQR = 0.5–4); mostly within 3 months. Common organ systems affected were pulmonary (14.2%), hematologic (14.0%), gastrointestinal (13.4%), and musculoskeletal (13.3%). Higher risk of severe irAEs was associated with pre-existing autoimmune disease (HR = 1.25, 95%&#xa0;CI&#xa0;=&#xa0;1.17–1.32), chemoimmunotherapy (HR = 2.35, 95%&#xa0;CI = 1.39–3.96), and longer diagnosis-to-treatment interval (HR = 1.50,&#xa0;95%&#xa0;CI = 1.31–1.60). Lower risks occurred among Black patients (HR = 0.56,&#xa0;95%CI = 0.34–0.92), those with baseline metastasis (HR = 0.84,&#xa0;95%&#xa0;CI&#xa0;=&#xa0;0.75–0.93), opioid use (HR = 0.68,&#xa0;95%&#xa0;CI = 0.54–0.87), and with atezolizumab (HR = 0.75,&#xa0;95%&#xa0;CI = 0.65–0.86) or nivolumab (HR = 0.91,&#xa0;95%&#xa0;CI&#xa0;=&#xa0;0.87–0.96) vs. pembrolizumab. The prediction model demonstrated good discrimination and calibration (bootstrap-corrected AUC = 0.85; Brier score = 0.14), supporting risk-stratified monitoring in patients receiving ICIs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Predictors of severe immune-related adverse events during first-line immune checkpoint inhibitor therapy for advanced non-small cell lung cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月4日

查看全文
  • Olajumoke A. Olateju,
  • Rajender R. Aparasu,
  • Meera Patel,
  • Tyler J. Varisco,
  • Chan Shen,
  • Meghana Trivedi,
  • Ekere J. Essien,
  • J. Douglas Thornton

摘要

Immune checkpoint inhibitors (ICIs) have transformed treatment for advanced non-small cell lung cancer (NSCLC) treatment but can trigger immune-related adverse events (irAEs). Evidence on clinically meaningful irAEs in first-line ICI settings is limited. Using the SEER-Medicare data (2010–2019), we conducted a population-based retrospective study of adults aged ≥ 66 years with advanced NSCLC initiating first-line nivolumab, pembrolizumab, or atezolizumab. Severe irAEs were defined as immune-related events requiring systemic immunosuppressants and resulting in ICI delay or discontinuation occurring after treatment initiation. Fine-Gray competing risks models were used to identify predictors of irAE, and model performance was evaluated using bootstrap and ten-fold cross-validation. Among 2,729 patients, 14.2% developed severe irAEs (median onset = 1.4 months; IQR = 0.5–4); mostly within 3 months. Common organ systems affected were pulmonary (14.2%), hematologic (14.0%), gastrointestinal (13.4%), and musculoskeletal (13.3%). Higher risk of severe irAEs was associated with pre-existing autoimmune disease (HR = 1.25, 95% CI = 1.17–1.32), chemoimmunotherapy (HR = 2.35, 95% CI = 1.39–3.96), and longer diagnosis-to-treatment interval (HR = 1.50, 95% CI = 1.31–1.60). Lower risks occurred among Black patients (HR = 0.56, 95%CI = 0.34–0.92), those with baseline metastasis (HR = 0.84, 95% CI = 0.75–0.93), opioid use (HR = 0.68, 95% CI = 0.54–0.87), and with atezolizumab (HR = 0.75, 95% CI = 0.65–0.86) or nivolumab (HR = 0.91, 95% CI = 0.87–0.96) vs. pembrolizumab. The prediction model demonstrated good discrimination and calibration (bootstrap-corrected AUC = 0.85; Brier score = 0.14), supporting risk-stratified monitoring in patients receiving ICIs.